Cargando…

Genomic landscape of TP53-mutated myeloid malignancies

Mostrar otras versiones (1)

TP53-mutated myeloid malignancies are associated with complex cytogenetics and extensive structural variants, which complicates detailed genomic analysis by conventional clinical techniques. We performed whole-genome sequencing (WGS) of 42 acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abel, Haley J., Oetjen, Karolyn A., Miller, Christopher A., Ramakrishnan, Sai M., Day, Ryan B., Helton, Nichole M., Fronick, Catrina C., Fulton, Robert S., Heath, Sharon E., Tarnawsky, Stefan P., Nonavinkere Srivatsan, Sridhar, Duncavage, Eric J., Schroeder, Molly C., Payton, Jacqueline E., Spencer, David H., Walter, Matthew J., Westervelt, Peter, DiPersio, John F., Ley, Timothy J., Link, Daniel C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425686/ https://www.ncbi.nlm.nih.gov/pubmed/37339484 http://dx.doi.org/10.1182/bloodadvances.2023010156

Ejemplares similares

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022)

Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia
por: Petti, Allegra A., et al.
Publicado: (2022)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53
por: Piqué-Borràs, Maria-Riera, et al.
Publicado: (2023)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions
por: DeZern, Amy E., et al.
Publicado: (2023)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
por: Short, Nicholas J., et al.
Publicado: (2023)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
por: Rodriguez-Zabala, Maria, et al.
Publicado: (2023)

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2023)

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
por: Bennett, Joshua, et al.
Publicado: (2023)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
por: Kemps, Paul G., et al.
Publicado: (2022)

A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms
por: Loh, Kah Poh, et al.
Publicado: (2022)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Coping strategies in patients with acute myeloid leukemia
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

Long-term outcomes among adults with Langerhans cell histiocytosis
por: Goyal, Gaurav, et al.
Publicado: (2023)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
por: Mueller, Sarah B., et al.
Publicado: (2022)

Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2(P95H) mutation
por: Xu, Jane Jialu, et al.
Publicado: (2022)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
por: Chovanec, Jack, et al.
Publicado: (2022)

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101
por: Ritchie, Ellen K., et al.
Publicado: (2022)

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study
por: Scott, Stuart, et al.
Publicado: (2023)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

A novel GATA2 distal enhancer mutation results in MonoMAC syndrome in 2 second cousins
por: West, Robert R., et al.
Publicado: (2023)

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories
por: Borate, Uma, et al.
Publicado: (2023)

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
por: Schnegg-Kaufmann, Annatina S., et al.
Publicado: (2023)

ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome
por: West, Robert R., et al.
Publicado: (2022)

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
por: McCarter, Joseph G. W., et al.
Publicado: (2023)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_79h9jkk7n4j919kk8tb08qs172